Therapeutic Options to Reduce Lp-PLA2 Levels and the Potential Impact on Vascular Risk Reduction

Overview

Journal Curr Treat Options Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2013 Mar 5

PMID 23456913

Citations 3

Authors

Koto Ishida

Brett Cucchiara

Affiliations

Soon will be listed here.

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme involved in the metabolism of Low-density lipoprotein (LDL) to pro-inflammatory mediators. Lp-PLA2 is highly expressed in the necrotic core of atherosclerotic plaques and has been associated with atherosclerotic plaque instability. Multiple studies have shown an association between elevated Lp-PLA2 levels and risk of both stroke and myocardial infarction, even after adjustment for standard vascular risk factors, and several professional organizations have recommended Lp-PLA2 as a potentially usefully tool to improve risk stratification for individual patients. Therapies directed at lowering Lp-PLA2 levels may represent a novel approach to reducing vascular risk, though direct clinical benefit from targeting treatment to Lp-PLA2 levels remains unproven. Statins appear to significantly lower Lp-PLA2 levels; fibrates and niacin may also lower Lp-PLA2 levels, though this is less well established. Darapladib, a potent, selective Lp-PLA2 inhibitor, is currently in phase III trials for prevention of recurrent vascular events in patients with coronary artery disease.

Citing Articles

Negative correlation between early recovery and lipoprotein-associated phospholipase A2 levels after intravenous thrombolysis.

Li Y, Wang W, Yang H, Guo W, Feng J, Yang D J Int Med Res. 2022; 50(4):3000605221093303.

PMID: 35441552 PMC: 9047848. DOI: 10.1177/03000605221093303.

Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis.

Qin Y, Qian X, Luo X, Li Y, Wang D, Jiang J Front Neurol. 2020; 11:574036.

PMID: 33178116 PMC: 7596647. DOI: 10.3389/fneur.2020.574036.

Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke.

Lin J, Zheng H, Cucchiara B, Li J, Zhao X, Liang X Neurology. 2015; 85(18):1585-91.

PMID: 26311748 PMC: 4642142. DOI: 10.1212/WNL.0000000000001938.

References

Ridker P, MacFadyen J, Wolfert R, Koenig W . Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial. Clin Chem. 2012; 58(5):877-86. DOI: 10.1373/clinchem.2011.180281. View

Cucchiara B, Messe S, Sansing L, Mackenzie L, Taylor R, Pacelli J . Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke. 2009; 40(7):2332-6. DOI: 10.1161/STROKEAHA.109.553545. View

Robins S, Collins D, Nelson J, Bloomfield H, Asztalos B . Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2008; 28(6):1172-8. DOI: 10.1161/ATVBAHA.107.160739. View

Packard C, OReilly D, Caslake M, McMahon A, Ford I, Cooney J . Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343(16):1148-55. DOI: 10.1056/NEJM200010193431603. View

Rimm E, Williams P, Fosher K, Criqui M, Stampfer M . Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ. 1999; 319(7224):1523-8. PMC: 28294. DOI: 10.1136/bmj.319.7224.1523. View

Wassertheil-Smoller S, Kooperberg C, McGinn A, Kaplan R, Hsia J, Hendrix S . Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension. 2008; 51(4):1115-22. DOI: 10.1161/HYPERTENSIONAHA.107.103721. View

Maki K, Bays H, Dicklin M, Johnson S, Shabbout M . Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011; 5(6):483-92. DOI: 10.1016/j.jacl.2011.09.001. View

Tselepis A, Panagiotakos D, Pitsavos C, Tellis C, Chrysohoou C, Stefanadis C . Smoking induces lipoprotein-associated phospholipase A2 in cardiovascular disease free adults: the ATTICA Study. Atherosclerosis. 2009; 206(1):303-8. DOI: 10.1016/j.atherosclerosis.2009.02.016. View

Elkind M, Leon V, Moon Y, Paik M, Sacco R . High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke. 2009; 40(10):3233-7. PMC: 2761676. DOI: 10.1161/STROKEAHA.109.552802. View

10.

Elkind M, Tai W, Coates K, Paik M, Sacco R . Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. Cerebrovasc Dis. 2008; 27(1):42-50. PMC: 2846303. DOI: 10.1159/000172633. View

11.

Cucchiara B, Kasner S . Use of statins in CNS disorders. J Neurol Sci. 2001; 187(1-2):81-9. DOI: 10.1016/s0022-510x(01)00529-9. View

12.

Serruys P, Garcia-Garcia H, Buszman P, Erne P, Verheye S, Aschermann M . Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008; 118(11):1172-82. DOI: 10.1161/CIRCULATIONAHA.108.771899. View

13.

. Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med. 2010; 268(4):348-58. DOI: 10.1111/j.1365-2796.2010.02258.x. View

14.

Persson M, Nilsson J, Nelson J, Hedblad B, Berglund G . The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis. 2006; 190(2):388-96. DOI: 10.1016/j.atherosclerosis.2006.02.016. View

15.

Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S . Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010; 375(9725):1536-44. PMC: 2864403. DOI: 10.1016/S0140-6736(10)60319-4. View

16.

Kuvin J, Dave D, Sliney K, Mooney P, Patel A, Kimmelstiel C . Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006; 98(6):743-5. DOI: 10.1016/j.amjcard.2006.04.011. View

17.

Nelson T, Hokanson J, Hickey M . Omega-3 fatty acids and lipoprotein associated phospholipase A(2) in healthy older adult males and females. Eur J Nutr. 2010; 50(3):185-93. DOI: 10.1007/s00394-010-0126-7. View

18.

Hatoum I, Nelson J, Cook N, Hu F, Rimm E . Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr. 2010; 91(3):786-93. PMC: 2824159. DOI: 10.3945/ajcn.2009.28870. View

19.

Saougos V, Tambaki A, Kalogirou M, Kostapanos M, Gazi I, Wolfert R . Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007; 27(10):2236-43. DOI: 10.1161/ATVBAHA.107.147280. View

20.

Mohler 3rd E, Ballantyne C, Davidson M, Hanefeld M, Ruilope L, Johnson J . The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized,.... J Am Coll Cardiol. 2008; 51(17):1632-41. DOI: 10.1016/j.jacc.2007.11.079. View